You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bruton tyrosine kinase inhibitor

Showing 1 - 25 of 9,603
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

Active, not recruiting
  • Multiple Sclerosis
  • tolebrutinib 60mg
  • tolebrutinib 120mg
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

CNS Lymphoma Trial in Petah Tikva (Imbruvica)

Recruiting
  • Central Nervous System Lymphoma
  • Petah Tikva, Israel
    Hematology Institute
May 9, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

Completed
Has Results
  • Hepatitis
  • Safety and Tolerability
  • HEPLISAV-B
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 13, 2022

Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

Not yet recruiting
  • CLL, Relapsed
  • +3 more
    • Clermont-Ferrand, France
    • +7 more
    Nov 16, 2022

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

    Active, not recruiting
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +9 more
    • BTK inhibitor PCI-32765
    • +5 more
    • Columbus, Ohio
      Ohio State University Medical Center
    Jun 27, 2022

    Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI

    Active, not recruiting
    Has Results
    • Safety and Tolerability
    • +3 more
    • Zoster Vaccine Recombinant, Adjuvanted
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 10, 2022

    Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

    Not yet recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 10, 2023

    Food Allergy, Food Allergy Peanut Trial in Baltimore (Acalabrutinib)

    Recruiting
    • Food Allergy
    • Food Allergy Peanut
    • Baltimore, Maryland
      Johns Hopkins Bayview Medical Center
    Dec 30, 2021

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 2, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 14, 2022

    Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

    Withdrawn
    • Recurrent Follicular Lymphoma
    • +8 more
    • (no location specified)
    Jun 2, 2022

    Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

    Recruiting
    • Blastoid Variant Mantle Cell Lymphoma
    • +8 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial (BGB-11417)

    Not yet recruiting
    • Leukemia
    • +4 more
    • (no location specified)
    Jul 27, 2022

    Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

    Recruiting
    • B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 9, 2022

    Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jul 12, 2023

    Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

    Suspended
    • Mantle Cell Lymphoma
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022

    Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in

    Recruiting
    • Autoimmune Hemolytic Anemia
    • +3 more
    • Duarte, California
      City of Hope Medical Center
    Mar 9, 2022

    Waldenstrom Macroglobulinemia Trial (Zanubrutinib)

    Not yet recruiting
    • Waldenstrom Macroglobulinemia
    • (no location specified)
    Nov 28, 2022

    Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)

    Recruiting
    • Relapsed Diffuse Large B-cell Lymphoma
    • Refractory Diffuse Large B-cell Lymphoma
    • Hefei, Anhui, China
    • +21 more
    Mar 2, 2022

    Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

    Recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 17, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Scottsdale, Arizona
    • +2 more
    Jan 5, 2023

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)

    Recruiting
    • Non Hodgkin Lymphoma
    • Diffuse Large B Cell Lymphoma
    • Nanjing, Jiangsu, China
    • +1 more
    Mar 9, 2022